New York, April 08, 2024 - PRISM MarketView - Clinical stage biotechnology company, Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), will publish an abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting which will take place from May 31 through June 4 in Chicago, Illinois. The abstract, titled “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts.
Lipella is advancing LP-50 for the treatment of non-muscle invasive bladder cancer (NMIBC). The compound has demonstrated the potential for increasing efficacy while minimizing systemic toxicity in preclinical studies.
There is a critical unmet need for effective treatment for NMIBC, which makes up 75-80% of newly diagnosed bladder cancers.
“ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC). Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.”
Dr. Jonathan Kaufman, Chief Executive Officer of Lipella
Lipella has made significant expansions to its pipeline in 2024. The company is advancing three IND-approved assets, two of which have been granted Orphan Disease Designation by the FDA.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) is featured on PRISM Emerging Pharma Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)